Cyted Health is a gastrointestinal health company founded in 2020 that develops a non-endoscopic diagnostic platform for early detection of esophageal diseases, including pre-cancerous conditions like Barrett's Esophagus and esophageal cancer.[1][2][4] Its core product, EndoSign®, is an FDA 510(k)-cleared capsule sponge device for minimally invasive esophageal cell collection, paired with advanced biomarker molecular testing and AI-driven analysis to enable accessible screening and monitoring.[2][4][5] Cyted serves healthcare providers, patients at risk for esophageal conditions, and pharma/life sciences partners, addressing the problem of low diagnosis rates—fewer than 10% of Barrett's Esophagus cases are identified pre-cancer—where only 1 in 5 esophageal cancer patients survive.[4] The company has raised $30.1M previously and $44M in Series B financing in August 2025 to fuel US expansion, UK consolidation, and new tests, showing strong growth with ongoing clinical studies like DETECT-ME (US enrollment since March 2025).[1][2][4]
Cyted was founded in 2020 by leading experts at the University of Cambridge, including CEO and co-founder Marcel Gehrung, emerging from research into minimally invasive cell collection and proprietary biomarker discovery for esophageal conditions.[2][4] The idea stemmed from the need to transform detection of pre-cancerous, cancerous, and inflammatory esophageal diseases, leveraging capsule sponge technology to make diagnostics faster, less invasive, and more scalable than traditional endoscopy.[1][5] Early traction included UK commercial success, incubation/accelerator stages, and pivotal FDA clearance for EndoSign®, setting the stage for global expansion; by 2025, it secured Series B funding backed by EQT Life Sciences and the British Business Bank, with endorsements from figures like Science Minister Lord Vallance highlighting its university-to-market impact.[1][2]
Cyted rides the wave of AI-enhanced precision diagnostics and non-invasive cancer screening, targeting the fastest-growing esophageal cancer amid rising GI disease burdens, where early detection could slash mortality.[4][5] Timing aligns with post-2020 medtech funding resurgence and FDA nods for capsule tech, amplified by market forces like aging populations, telemedicine growth, and pharma demand for biomarkers in trials.[2][5] It influences the ecosystem by partnering with universities, NHS-like systems, and investors like EQT, pushing capsule sponges into frontline care and enabling population-scale screening (e.g., BEST4's 140,000 patients), potentially redefining GI standards beyond endoscopy giants.[2][5]
Cyted is poised to dominate non-endoscopic esophageal diagnostics, with US commercialization via DETECT-ME results, portfolio expansion, and Series B-fueled hires driving 2026 growth.[2][4] Trends like AI biomarker acceleration and value-based care will amplify its edge, evolving it from UK pioneer to global leader—potentially capturing a slice of the $10B+ GI diagnostics market. Watch for pharma integrations and BEST4 outcomes to cement its life-saving trajectory, transforming "earlier matters" from slogan to standard.[4][5]
Cyted has raised $61.0M in total across 2 funding rounds.
Cyted's investors include Advent Life Sciences, Business Growth Fund, EQT Life Sciences, General Catalyst.
Cyted has raised $61.0M across 2 funding rounds. Most recently, it raised $44.0M Series B in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2025 | $44.0M Series B | Advent Life Sciences, Business Growth Fund, EQT Life Sciences, General Catalyst | |
| May 1, 2023 | $17.0M Series A | Business Growth Fund, General Catalyst |
